Perceptions of Statin Discontinuation among Patients with Life-Limiting Illness

Journal of Palliative Medicine
Jennifer TjiaJon P Furuno

Abstract

Optimal management of chronic medications for patients with life-limiting illness is uncertain. Medication deprescribing may improve outcomes in this population, but patient concerns regarding deprescribing are unclear. The aim of this study was to quantify the perceived benefits and concerns of statin discontinuation among patients with life-limiting illness. Baseline data from a multicenter, pragmatic clinical trial of statin discontinuation were used. Cognitively intact participants with a life expectancy of 1-12 months receiving statin medications for primary or secondary prevention were enrolled. Responses to a 9-item questionnaire addressing patient concerns about discontinuing statins were collected. We used Pearson chi-square tests to compare responses by primary life-limiting diagnosis (cancer, cardiovascular disease, other). Of 297 eligible participants, 58% had cancer, 8% had cardiovascular disease, and 30% other primary diagnoses. Mean (standard deviation) age was 72 (11) years. Fewer than 5% of participants expressed concern that statin deprescribing indicated physician abandonment. About one in five participants reported being told to take statins for the rest of their life (18%) or feeling that discontinuation re...Continue Reading

Associated Clinical Trials

References

Mar 4, 2000·BMJ : British Medical Journal·N BrittenC P Bradley
Mar 29, 2006·Archives of Internal Medicine·Holly M HolmesGreg A Sachs
Apr 3, 2007·Journal of the American Geriatrics Society·David C CurrowTania M Shelby-James
Sep 6, 2008·Journal of the American Geriatrics Society·Kevin T BainStephen G Pauker
Nov 28, 2008·Clinical Pharmacology and Therapeutics·H M Holmes
Apr 17, 2012·Clinics in Geriatric Medicine·Jennifer Tjia, Jane Givens
May 31, 2012·Drugs & Aging·Alfonso J Cruz-JentoftLourdes Rexach
Oct 12, 2012·International Journal of Clinical Pharmacy·Emily ReeveMichael D Wiese
Aug 6, 2013·Drugs & Aging·Emily ReeveMichael D Wiese
Sep 14, 2013·Journal of the American Geriatrics Society·Emily ReeveSepehr Shakib
Apr 1, 2011·Therapeutic Advances in Drug Safety·Christopher BeerAlasdair Millar
Sep 27, 2014·Journal of Palliative Medicine·Jennifer TjiaLee Ellington
Oct 9, 2014·The Medical Journal of Australia·Ian A ScottDanielle A Stowasser
Mar 24, 2015·JAMA Internal Medicine·Holly M Holmes, Adam Todd
Jun 7, 2015·International Journal of Clinical Pharmacy·Katie QiDanijela Gnjidic

❮ Previous
Next ❯

Citations

Apr 17, 2018·The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences·Timo E StrandbergHannu Kautiainen
Sep 20, 2018·Palliative Medicine·Kristel PaqueThierry Christiaens
Oct 22, 2018·Biology of Sex Differences·Helena BergströmLinda Björkhem-Bergman
Aug 14, 2020·Journal of the American Geriatrics Society·Carolyn T ThorpeJoseph T Hanlon
Dec 4, 2020·Journal of the American Geriatrics Society·Deborah S MackKate L Lapane
May 1, 2021·Pharmaceuticals·Gabriella FriskLinda Björkhem-Bergman

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.